Hamburg Gives Rallying Cry For FDA Power In Her Public Farewell
This article was originally published in The Tan Sheet
Executive Summary
The outgoing commissioner gives forceful defense of the agency’s regulatory authority and warns that lowering drug approval standards would damage patients and industry.
You may also be interested in...
Hamburg Departure Hinged On Filling FDA Leadership Roster
Susan Mayne brings “new strength and focus to CFSAN and medical countermeasures expert Luciana Borio moves to chief scientist role. Hamburg offers previews on leadership approaches of Stephen Ostroff and Robert Califf.
Rezafungin Review Highlights US FDA’s ‘Flexible Development' Approach For Antimicrobials
Cidara developed the antifungal for candidemia/invasive candidiasis pursuant to the FDA’s 2017 ‘Unmet Need guidance,’ which provides an avenue for approval with a 'limited use' indication based on a streamlined development program. Some of the guidance recommendations also have been leveraged under the LPAD pathway.
Two Years In US Accelerated Approval Withdrawals
Twenty accelerated approval indications have been voluntarily withdrawn by sponsors since December 2020, most coming as a result of the FDA cancer office’s push to rid labeling of ‘dangling’ and ‘delinquent’ indications that lack confirmation of clinical benefit.